	Current review*, 2021	Edris, 2021 PMID 33988014	Edris, 2019 PMID 31395084
Outcome(s)			
	ARAE* in all patients with severe asthma		
RR (95% CI)	0.38 (0.26-0.58)	d = 1.13 (-0.23 to 2.76) (insignificant)	d = 1.17 (-0.68 to 3.15) (insignificant)
Heterogeneity	62% (CI: 0% to 91%)	NA (network meta-analysis)	NA (network meta-analysis)
Summary of important differences or findings	Included Menzies-Gow (NAVIGATOR) and subgrouped results by baseline eosinophil counts		
	ARAE† in all patients with severe asthma and *low* blood eosinophil counts		
RR (95% CI)	0.47 (0.26-0.86)	NA	NA
Heterogeneity	61% (CI: 0% to 91%)	NA	NA
	ARAE† in all patients with severe asthma and *high* blood eosinophil counts		
RR (95% CI)	0.30 (0.22-0.40)	NA	NA
Heterogeneity	0%	NA	NA
Studies included			
Corren (PATHWAY), 2017	Yes	Yes	Yes
Menzies-Gow (NAVIGATOR), 2021	Yes	NA	NA
Notes			

NA. Not available.

RR. Risk Ratio.

D. Cohen's d effect difference.

RRR. Relative risk ratio.

CI. Confidence Interval.

* https://openmetaanalysis.github.io/asthma/

† ARAE. Annualized rate of asthma exacerbations.